StockData
Gyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc. (GYRE) stock

GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3014% below fair value
$4.56+0.17 (+3.87%)

Close on Nov 17, 2026Market cap $508.49MP/E –Yield –

Gyre Therapeutics, Inc. saw revenue fall 3.7% to $108.15M over the twelve months to Sep 30, 2026. Operating income fell 809.3% to -$15.55M, moving the operating margin from 2.0% to -14.4%. Free cash flow was -$7.75M. At the latest close the market valued the company at $508.49M.

Revenue
$108.15M
-3.7% vs. a year earlier
Operating income
-$15.55M
-809.3% vs. a year earlier
Free cash flow
-$7.75M
TTM Q3 2026
EPS, diluted
-$0.23
TTM Q3 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026

Valuation

Market cap
$508.49M
P/E ratio
–
Price to sales
4.70
Price to book
4.71
Dividend yield
–
Free cash flow yield
-1.52%

Fundamentals

Revenue
$108.15M
Net income
-$36.65M
EPS, diluted
-$0.23
Free cash flow
-$7.75M
Book value per share
$1.02
Diluted shares
106M

Trading

Next earnings
Mar 11, 2027 (estimated, after the close)
Previous close
$4.39
Open
$4.39
Day's range
$4.32 – $4.60
Volume
215,957
Average volume (20 days)
226,525
Index membership
Russell 2000 (since Sep 2024)
52-week range
$3.97 – $9.14
RSI (14 days)
39.8
Volatility (1 year)
67.0%
Relative volume
1.61×

Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2010, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodGYRES&P 500DifferenceGYRE per yearS&P 500 per year
1 month-25.0%-4.0%−21.0 pts
3 months-33.0%-5.0%−28.1 pts
Year to date-35.4%+8.2%−43.7 pts
1 year-43.1%+11.2%−54.4 pts
3 years-69.0%+68.5%−137.5 pts-32.3%+19.0%
5 years-65.9%+67.3%−133.2 pts-19.4%+10.8%
10 years-95.5%+291.6%−387.1 pts-26.6%+14.6%

Fifteen years at a glance

Fiscal years 2011 to 2025 and trailing twelve months, USD

Revenue

$108.15M-3.7% YoY

Gross profit

$101.02M-1.4% YoY

Operating income

-$15.55M-809.3% YoY

Net income

-$36.65M-801.1% YoY

EPS, diluted

-$0.23

Free cash flow

-$7.75M
Reported periodTrailing twelve months

Press releases

Releases Gyre Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Gyre Therapeutics

Pharmaceutical Preparations

Gyre Therapeutics, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule therapies targeting organ fibrosis and inflammatory conditions. The company's commercial portfolio includes ETUARY (pirfenidone) and Etorel (nintedanib) for idiopathic pulmonary fibrosis and other interstitial lung disorders, as well as Contiva (avatrombopag) for thrombocytopenia associated with chronic liver disease. Its clinical pipeline features Hydronidone for liver fibrosis, along with candidates addressing acute liver failure, pulmonary arterial hypertension, and chronic obstructive pulmonary disease. Gyre supplies therapies to adult patients requiring specialized pulmonary, hepatologic, and hospital-based medical care.

Company profile, executives and history

Gyre Therapeutics stock: common questions

What is Gyre Therapeutics's stock price?

GYRE closed at $4.56 on Nov 17, 2026, up 3.87% on the day. Over the past 52 weeks it traded between $3.97 and $9.14.

What is Gyre Therapeutics's market cap?

Gyre Therapeutics was worth $508.49M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is GYRE's P/E ratio?

Gyre Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.23), so it has no meaningful P/E ratio.

How much revenue does Gyre Therapeutics make?

Gyre Therapeutics reported revenue of $108.15M for the twelve months to Sep 30, 2026, down 3.7% from a year earlier.

Does Gyre Therapeutics pay a dividend?

No. Gyre Therapeutics has not paid a cash dividend over the last twelve months.

When does Gyre Therapeutics report earnings next?

Gyre Therapeutics is expected to report Q4 FY2026 results on Mar 11, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.

How has GYRE stock performed over the past year?

Including dividends, GYRE returned -43.1% over the past year, against +11.2% for the S&P 500.

How many GYRE shares are sold short?

2M shares were sold short at the latest FINRA report, 32.40% of the float, or 14.2 days of average trading volume.

Who are Gyre Therapeutics's competitors?

Companies most similar to Gyre Therapeutics by business, industry and size include GOSS, CYTK, ZVRA, RCUS, ETON.

See a number that looks wrong?